United Therapeutics Corporation
Extract: Bylaws Amended/Restated (Plain English Desc) from a 8-K on 06/29/2020   Download
SEC Document
SEC Filing

Following shareholder approval of the Declassification Amendment, the Board also approved conforming amendments to Article III, Sections 3.1 and 3.2 of the Company’s Seventh Amended and Restated By-laws (the “By-laws”). The By-law amendments also clarify that any director elected to fill a new Board seat resulting from an increase in the number of directors after the effective date of the Declassification Amendment would be elected for a term expiring at the next succeeding annual meeting of shareholders. Directors elected by the Board to fill vacancies would have the same remaining terms as that of their predecessors. The amendments to the By-laws became effective upon filing of the Declassification Amendment with the Delaware Secretary of State on June 26, 2020.